Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Amortizatization of Intangibles (2019 - 2025)

Historic Amortizatization of Intangibles for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $1.7 million.

  • C4 Therapeutics' Amortizatization of Intangibles rose 458.49% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 445.46%. This contributed to the annual value of $6.4 million for FY2024, which is 425.39% up from last year.
  • C4 Therapeutics' Amortizatization of Intangibles amounted to $1.7 million in Q3 2025, which was up 458.49% from $1.7 million recorded in Q2 2025.
  • C4 Therapeutics' Amortizatization of Intangibles' 5-year high stood at $1.7 million during Q2 2022, with a 5-year trough of -$1.7 million in Q3 2021.
  • Over the past 5 years, C4 Therapeutics' median Amortizatization of Intangibles value was $1.5 million (recorded in 2023), while the average stood at $1.1 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first tumbled by 92709.36% in 2021, then surged by 42171.25% in 2022.
  • Over the past 5 years, C4 Therapeutics' Amortizatization of Intangibles (Quarter) stood at -$847000.0 in 2021, then soared by 277.33% to $1.5 million in 2022, then grew by 4.06% to $1.6 million in 2023, then increased by 4.35% to $1.6 million in 2024, then rose by 3.49% to $1.7 million in 2025.
  • Its Amortizatization of Intangibles was $1.7 million in Q3 2025, compared to $1.7 million in Q2 2025 and $1.6 million in Q1 2025.